Xenofon Baraliakos, MD

Rheumazentrum Ruhrgebiet Herne
Herne, Germany

Dr Xenofon Baraliakos is the Medical Director at the Rheumazentrum Ruhrgebiet Herne and University Professor for Internal Medicine and Rheumatology at the Ruhr-University Bochum, Germany.

He studied Human Medicine at the universities of Magdeburg and Berlin, Germany and went on to receive a PhD degree in 2005 with a thesis entitled ‘MRI examinations of the spine in patients with ankylosing spondylitis before and after therapy with monoclonal antibodies against TNFα’.

Dr. Baraliakos received his official Board Degrees in orthopaedic surgery in 2007 and in Internal Medicine and Rheumatology in 2014. His research interests include clinical and academic research in the field of spondyloarthritides, with special emphasis on imaging outcomes and treatment of the disease.

Among others, Dr Baraliakos won the EWRR Award, in 2005, the EULAR Young Investigator Award, in 2006 and 2008, the German patient’s AS Society Award in 2010 and the 2014 Award for Excellence in Clinical Research from the European Society for Clinical Investigations.

Dr Baraliakos is the current President of ASAS (Assessment of Spondyloarthritis International Society) and Past Chair of the EULAR standing committee for musculoskeletal imaging and member of the EULAR Executive Committee.
He holds membership of the ACR, GRAPPA and the German Society of Rheumatology. He also acts as a reviewer and is an Associate Editor in a number of major rheumatological journals.

Disclosure information not submitted.

Presentation(s):

517: CH Spondylarthritis and Psoriatic Arthritis: Updates from Research Organizations
Friday, November 11, 2022
6:00 PM – 7:00 PM Eastern Time
0411: Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
0414: Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
0420: What Does It Mean - A Good Response to NSAIDs? A Systematic Comparison of Patients with Axial Spondyloarthritis and Controls with Chronic Back Pain
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
0411: Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
Sunday, November 13, 2022
9:10 AM – 9:15 AM Eastern Time
1010: Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
Sunday, November 13, 2022
9:00 AM – 10:30 AM Eastern Time
1037: Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies
Sunday, November 13, 2022
9:00 AM – 10:30 AM Eastern Time
1156: Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in Patients with Active Ankylosing Spondylitis (AS) and Persists Despite Anti-TNF Treatment
Sunday, November 13, 2022
1:00 PM – 3:00 PM Eastern Time
1243: The Impact of MRI Slice Thickness on the Detection of Spinal Syndesmophytes in Axial Spondyloarthritis
Sunday, November 13, 2022
1:00 PM – 3:00 PM Eastern Time
1509: Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations
Sunday, November 13, 2022
1:00 PM – 3:00 PM Eastern Time
1774: Performance of an Early Triage System for Identification of Patients with Inflammatory Rheumatic Diseases
Sunday, November 13, 2022
2:40 PM – 2:45 PM Eastern Time
Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis/Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study
Monday, November 14, 2022
1:05 PM – 1:15 PM Eastern Time
1769: Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time
1774: Performance of an Early Triage System for Identification of Patients with Inflammatory Rheumatic Diseases
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time
1801: High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time
L14: Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time
L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time
L14: Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Monday, November 14, 2022
2:35 PM – 2:40 PM Eastern Time
L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
Monday, November 14, 2022
2:40 PM – 2:45 PM Eastern Time